Oncolytic viruses for induction of anti-tumor immunity

Current Pharmaceutical Biotechnology

Volumn 13, Issue 9, 2012, Pages 1750-1760

  Tong, Alex W ^a   Senzer, Neil ^a,b,c,d   Cerullo, Vincenzo ^e   Templeton, Nancy Smyth ^a   Hemminki, Akseli ^e   Nemunaitis, John ^a,b,c,d  

^a GRADALIS INC   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c TEXAS ONCOLOGY   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Ad 24; Cationic liposome encapsulation; GMCSF; Oncolytic virus; ONCOVEX; Stealthed virus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; LONTUCIREV; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 5 DELTA 24 GM CSF; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHOROID MELANOMA; CLINICAL EFFECTIVENESS; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GENETIC ENGINEERING; HEAD AND NECK CANCER; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INJECTION SITE PAIN; INTESTINE CARCINOMA; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; META ANALYSIS (TOPIC); NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; STOMACH CANCER; SYNOVIAL SARCOMA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; VIRUS GENOME; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

HERPES;

EID: 84863547754     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800958913     Document Type: Article

References (148)

1. Alemany, R. Cancer selective adenoviruses. Mol. Aspects Med., 2007, 28 (1), 42-58.
2. Crompton, A. M.; Kirn, D. H. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr. Cancer Drug Targets, 2007, 7 (2), 133-139.
3. Everts, B.; van der Poel, H. G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther., 2005, 12 (2), 141-161.
4. Hedley, S. J.; Chen, J.; Mountz, J. D.; Li, J.; Curiel, D. T.; Korokhov, N.; Kovesdi, I. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol. Immunother., 2006, 55 (11), 1412-1419.
5. Kelly, E.; Russell, S. J. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007, 15 (4), 651-659.
6. Lin, E.; Nemunaitis, J. Oncolytic viral therapies. Cancer Gene Ther., 2004, 11 (10), 643-664.
7. Liu, T. C.; Hwang, T. H.; Bell, J. C.; Kirn, D. H. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther 2008, 16 (6), 1006-1008.
8. Parato, K. A.; Senger, D.; Forsyth, P. A.; Bell, J. C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer, 2005, 5 (12), 965-976.
9. Vile, R.; Ando, D.; Kirn, D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther., 2002, 9 (12), 1062-1067.
10. Young, L. S.; Searle, P. F.; Onion, D.; Mautner, V. Viral gene therapy strategies: from basic science to clinical application. J. Pathol., 2006, 208 (2), 299-318.
11. Tong, A. W. Oncolytic viral therapy for human cancer: challenges revisited (review). Drug Devel Res., 2006, 66, 260-277.
12. Short, J. J.; Curiel, D. T. Oncolytic adenoviruses targeted to cancer stem cells. Mol. Cancer Ther., 2009, 8 (8), 2096-2102.
13. Harrington, K. J.; Melcher, A.; Vassaux, G.; Pandha, H. S.; Vile, R. G. Exploiting synergies between radiation and oncolytic viruses. Curr. Opin. Mol. Ther., 2008, 10 (4), 362-370.
14. Ribacka, C.; Pesonen, S.; Hemminki, A. Cancer, stem cells, and oncolytic viruses. Ann. Med., 2008, 40 (7), 496-505.
15. Nemunaitis, J.; Cunningham, C.; Tong, A. W.; Post, L.; Netto, G.; Paulson, A. S.; Rich, D.; Blackburn, A.; Sands, B.; Gibson, B.; Randlev, B.; Freeman, S. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther., 2003, 10 (5), 341-352.
16. Nemunaitis, J.; Senzer, N.; Sarmiento, S.; Zhang, Y. A.; Arzaga, R.; Sands, B.; Maples, P.; Tong, A. W. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther., 2007, 14 (11), 885-893.
17. Pesonen, S.; Nokisalmi, P.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Kangasniemi, L.; Laasonen, L.; Ribacka, C.; Guse, K.; Haavisto, E.; Oksanen, M.; Rajecki, M.; Helminen, A.; Ristimaki, A.; Karioja-Kallio, A.; Karli, E.; Kantola, T.; Bauerschmitz, G.; Kanerva, A.; Joensuu, T.; Hemminki, A. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther., 2010, 17(7),892-904
18. Cerrullo, V.; Pesonen, S.; Diaconu, I.; Escutenaire, S.; Arstilla, P.; Ugolini, M.; Nikosalmi, P.; Raki, M.; Laasonen, L.; Sarkioja, M.; Rajeckin, M.; Kangasniemi, L.; Guse, K.; Helminen, A.; Ahtiainen, L.; Ristimaki, A.; Raisanen-Sokolowski, A.; Haavisto, E.; Oksanen, M.; Karli, E.; Karioja-Kallio, A.; Holm, S.L.; Kouri, M.; Joensuu, T.; Kanerva, A.; Hemminki, A. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor (GMCSF) induces anti-tumoral immunity in cancer patients. Cancer Res., 2010, 70(11), 4297-4309
19. Nokisalmi, P.P.S.; Escutenaire, S.; Särkioja, M.; Raki, M.; Cerullo, V.; Laasonen, L.; Alemany, R.; Rojas, J.J.; Guse, K.; Rajecki, M.; Kangasniemi, L.; Helminen, A.; Haavisto, E.; Oksanen, M.; Karioja-Kallio, A.; Kanerva, A.; Joensuu, T.; Ahtiainen, L.; Hemminki, A. Oncolytic adenovirus ICOVIR-7 shows good safety and immunological efficacy in cancer patient treatments. Clin. Cancer Res., 2010.
20. Jia, H.; Kling, J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006, 24 (2), 117-118.
21. Cuesta, R.; Xi, Q.; Schneider, R. J. Structural basis for competitive inhibition of eIF4G-Mnk1 interaction by the adenovirus 100- kilodalton protein. J. Virol., 2004, 78 (14), 7707-7716.
22. Chiocca, E. A.; Abbed, K. M.; Tatter, S.; Louis, D. N.; Hochberg, F. H.; Barker, F.; Kracher, J.; Grossman, S. A.; Fisher, J. D.; Carson, K.; Rosenblum, M.; Mikkelsen, T.; Olson, J.; Markert, J.; Rosenfeld, S.; Nabors, L. B.; Brem, S.; Phuphanich, S.; Freeman, S.; Kaplan, R.; Zwiebel, J. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther., 2004, 10 (5), 958-966.
23. Galanis, E.; Okuno, S. H.; Nascimento, A. G.; Lewis, B. D.; Lee, R. A.; Oliveira, A. M.; Sloan, J. A.; Atherton, P.; Edmonson, J. H.; Erlichman, C.; Randlev, B.; Wang, Q.; Freeman, S.; Rubin, J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther., 2005, 12 (5), 437-445.
24. Ganly, I.; Kirn, D.; Eckhardt, G.; Rodriguez, G. I.; Soutar, D. S.; Otto, R.; Robertson, A. G.; Park, O.; Gulley, M. L.; Heise, C.; Von Hoff, D. D.; Kaye, S. B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 2000, 6 (3), 798-806.
25. Habib, N.; Salama, H.; Abd El Latif Abu Median, A.; Isac Anis, I.; Abd Al Aziz, R. A.; Sarraf, C.; Mitry, R.; Havlik, R.; Seth, P.; Hartwigsen, J.; Bhushan, R.; Nicholls, J.; Jensen, S. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther., 2002, 9 (3), 254-259.
26. Habib, N. A.; Sarraf, C. E.; Mitry, R. R.; Havlik, R.; Nicholls, J.; Kelly, M.; Vernon, C. C.; Gueret-Wardle, D.; El-Masry, R.; Salama, H.; Ahmed, R.; Michail, N.; Edward, E.; Jensen, S. L. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther., 2001, 12 (3), 219-226.
27. Hamid, O.; Varterasian, M. L.; Wadler, S.; Hecht, J. R.; Benson, A. 3rd; Galanis, E.; Uprichard, M.; Omer, C.; Bycott, P.; Hackman, R. C.; Shields, A. F. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol., 2003, 21 (8), 1498-1504.
28. Hecht, J. R.; Bedford, R.; Abbruzzese, J. L.; Lahoti, S.; Reid, T. R.; Soetikno, R. M.; Kirn, D. H.; Freeman, S. M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res., 2003, 9 (2), 555-561.
29. Khuri, F. R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I. F.; Romel, L.; Gore, M.; Ironside, J.; MacDougall, R. H.; Heise, C.; Randlev, B.; Gillenwater, A. M.; Bruso, P.; Kaye, S. B.; Hong, W. K.; Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively- replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 2000, 6 (8), 879-885.
30. Morley, S.; MacDonald, G.; Kirn, D.; Kaye, S.; Brown, R.; Soutar, D. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin. Cancer Res., 2004, 10 (13), 4357-4362.
31. Mulvihill, S.; Warren, R.; Venook, A.; Adler, A.; Randlev, B.; Heise, C.; Kirn, D. Safety and feasibility of injection with an E1B- 55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene. Ther., 2001, 8 (4), 308-315.
32. Nemunaitis, J.; Cunningham, C.; Buchanan, A.; Blackburn, A.; Edelman, G.; Maples, P.; Netto, G.; Tong, A.; Randlev, B.; Olson, S.; Kirn, D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene. Ther., 2001, 8 (10), 746-759.
33. Nemunaitis, J.; Ganly, I.; Khuri, F.; Arseneau, J.; Kuhn, J.; McCarty, T.; Landers, S.; Maples, P.; Romel, L.; Randlev, B.; Reid, T.; Kaye, S.; Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res., 2000, 60 (22), 6359-6366.
34. Nemunaitis, J.; Khuri, F.; Ganly, I.; Arseneau, J.; Posner, M.; Vokes, E.; Kuhn, J.; McCarty, T.; Landers, S.; Blackburn, A.; Romel, L.; Randlev, B.; Kaye, S.; Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 2001, 19 (2), 289-298.
35. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Wein, L. M.; Andrews, J.; Randlev, B.; Heise, C.; Uprichard, M.; Hatfield, M.; Rome, L.; Rubin, J.; Kirn, D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res., 2002, 62 (21), 6070-6079.
36. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Andrews, J.; Romel, L.; Hatfield, M.; Rubin, J.; Kirn, D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene. Ther., 2001, 8 (21), 1618-1626.
37. Reid, T.; Warren, R.; Kirn, D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene. Ther., 2002, 9 (12), 979-986.
38. Reid, T. R.; Freeman, S.; Post, L.; McCormick, F.; Sze, D. Y. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene. Ther., 2005, 12 (8), 673-681.
39. Sze, D. Y.; Freeman, S. M.; Slonim, S. M.; Samuels, S. L.; Andrews, J. C.; Hicks, M.; Ahrar, K.; Gupta, S.; Reid, T. R. Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J. Vasc. Interv. Radiol., 2003, 14 (3), 279-290.
40. Vasey, P. A.; Shulman, L. N.; Campos, S.; Davis, J.; Gore, M.; Johnston, S.; Kirn, D. H.; O'Neill, V.; Siddiqui, N.; Seiden, M. V.; Kaye, S. B. Phase I trial of intraperitoneal injection of the E1B-55- kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol., 2002, 20 (6), 1562-1569.
41. Garber, K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst., 2006, 98 (5), 298-300.
42. Yu, W.; Fang, H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets, 2007, 7 (2), 141-148.
43. Kanerva, A.; Zinn, K. R.; Chaudhuri, T. R.; Lam, J. T.; Suzuki, K.; Uil, T. G.; Hakkarainen, T.; Bauerschmitz, G. J.; Wang, M.; Liu, B.; Cao, Z.; Alvarez, R. D.; Curiel, D. T.; Hemminki, A. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptortargeted oncolytic adenovirus. Mol. Ther., 2003, 8 (3), 449-458.
44. Alemany, R.; Balague, C.; Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 2000, 18 (7), 723-727.
45. Heise, C.; Hermiston, T.; Johnson, L.; Brooks, G.; Sampson- Johannes, A.; Williams, A.; Hawkins, L.; Kirn, D. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat. Med., 2000, 6 (10), 1134-1139.
46. Ying, B.; Wold, W. S. Adenovirus ADP protein (E3-11.6K), which is required for efficient cell lysis and virus release, interacts with human MAD2B. Virology, 2003, 313 (1), 224-234.
47. Tollefson, A. E.; Ryerse, J. S.; Scaria, A.; Hermiston, T. W.; Wold, W. S. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology, 1996, 220 (1), 152-162.
48. Tollefson, A. E.; Scaria, A.; Hermiston, T. W.; Ryerse, J. S.; Wold, L. J.; Wold, W. S. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol., 1996, 70 (4), 2296-2306.
49. Cascallo, M.; Alonso, M. M.; Rojas, J. J.; Perez-Gimenez, A.; Fueyo, J.; Alemany, R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther., 2007, 15 (9), 1607-1615.
50. Nemunaitis, J.; Vorhies, J. S.; Pappen, B.; Senzer, N. 10-year follow- up of gene-modified adenoviral-based therapy in 146 nonsmall- cell lung cancer patients. Cancer Gene. Ther., 2007, 14 (8), 762-763.
51. Kaur, B.; Cripe, T. P.; Chiocca, E. A. Buy one get one free: armed viruses for the treatment of cancer cells and their microenvironment. Curr. Gene Ther., 2009, 9 (5), 341-355.
52. Kirn, D. H.; Thorne, S. H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer, 2009, 9 (1), 64-71.
53. Cattaneo, R.; Miest, T.; Shashkova, E. V.; Barry, M. A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol., 2008, 6 (7), 529-40.
54. Templeton, N. S. Developments in liposomal gene delivery systems. Exp. Opin. Biol. Ther., 2001, 1 (4), 567-570.
55. Yotnda, P.; Chen, D. H.; Chiu, W.; Piedra, P. A.; Davis, A.; Templeton, N. S.; Brenner, M. K. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol. Ther., 2002, 5 (3), 233-2341.
56. Yotnda, P.; Davis, A. R.; Hicks, M. J.; Templeton, N. S.; Brenner, M. K. Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol. Ther., 2004, 9 (4), 489-495.
57. Seiler, M. P.; Cerullo, V.; Lee, B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene. Ther., 2007, 7 (5), 297-305.
58. Cerullo, V.; Seiler, M. P.; Mane, V.; Brunetti-Pierri, N.; Clarke, C.; Bertin, T. K.; Rodgers, J. R.; Lee, B. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol. Ther., 2007, 15 (2), 378-385.
59. Alemany, R.; Cascallo, M. Oncolytic viruses from the perspective of the immune system. Future Microbiol., 2009, 4, 527-536.
60. Muruve, D. A. The innate immune response to adenovirus vectors. Hum. Gene. Ther., 2004, 15 (12), 1157-1166.
61. Bowie, A. G.; Unterholzner, L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol., 2008, 8 (12), 911-22.
62. Tuve, S.; Liu, Y.; Tragoolpua, K.; Jacobs, J. D.; Yumul, R. C.; Li, Z. Y.; Strauss, R.; Hellstrom, K. E.; Disis, M. L.; Roffler, S.; Lieber, A. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine, 2009, 27 (31), 4225-4239.
63. Kirn, D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Exp. Opin. Biol. Ther., 2001, 1, (3), 525-538.
64. Kirn, D.; Martuza, R. L.; Zwiebel, J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med., 2001, 7 (7), 781-787.
65. Kirn, D. Clinical research results with dl1520 (Onyx-015), a replication- selective adenovirus for the treatment of cancer: what have we learned? Gene. Ther., 2001, 8 (2), 89-98.
66. Bernt, K. M.; Ni, S.; Tieu, A. T.; Lieber, A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res., 2005, 65 (10), 4343-4352.
67. Geutskens, S. B.; van der Eb, M. M.; Plomp, A. C.; Jonges, L. E.; Cramer, S. J.; Ensink, N. G.; Kuppen, P. J.; Hoeben, R. C. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther., 2000, 7 (16), 1410-1416.
68. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454 (7203), 436-444.
69. VanOosten, R. L.; Griffith, T. S. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res., 2007, 67 (24), 11980-11990.
70. Ren, T.; Wen, Z. K.; Liu, Z. M.; Qian, C.; Liang, Y. J.; Jin, M. L.; Cai, Y. Y.; Xu, L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Cancer Invest, 2008, 26 (5), 448-455.
71. Sun, Y.; Peng, D.; Lecanda, J.; Schmitz, V.; Barajas, M.; Qian, C.; Prieto, J. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene. Ther., 2000, 7 (17), 1467-1476.
72. Molinier-Frenkel, V.; Lengagne, R.; Gaden, F.; Hong, S. S.; Choppin, J.; Gahery-Segard, H.; Boulanger, P.; Guillet, J. G. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol., 2002, 76 (1), 127-135.
73. Miller, G.; Lahrs, S.; Pillarisetty, V. G.; Shah, A. B.; DeMatteo, R. P. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res., 2002, 62 (18), 5260-5266.
74. Senzer, N.; Mani, S.; Rosemurgy, A.; Nemunaitis, J.; Cunningham, C.; Guha, C.; Bayol, N.; Gillen, M.; Chu, K.; Rasmussen, C.; Rasmussen, H.; Kufe, D.; Weichselbaum, R.; Hanna, N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol., 2004, 22 (4), 592-601.
75. Weichselbaum, R. R.; Kufe, D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene. Ther., 2009, 16(8),609-619
76. Sarkar, D.; Su, Z. Z.; Vozhilla, N.; Park, E. S.; Randolph, A.; Valerie, K.; Fisher, P. B. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res., 2005, 65 (19), 9056-9063.
77. Dranoff, G.; Jaffee, E.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Jackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 1993, 90 (8), 3539-3543.
78. Dessureault, S.; Noyes, D.; Lee, D.; Dunn, M.; Janssen, W.; Cantor, A.; Sotomayor, E.; Messina, J.; Antonia, S. J. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol., 2007, 14 (2), 869-884.
79. Eager, R.; Nemunaitis, J. GM-CSF gene-transduced tumor vaccines. Mol. Ther., 2005, 12 (1), 18-27.
80. Maung, K.; Nemunaitis, J.; Cunningham, C. Granulocyte macrophage colony-stimulating factor (GM-CSF) gene-transduced tumor vaccines (GVAX) in non-small-cell lung cancer. Clin. Lung Cancer, 2001, 3 (1), 25-26.
81. Nemunaitis, J.; Appelbaum, F.; Singer, J. Effect of GM-CSF on circulating granulocyte-monocyte progenitors in autologous bone marrow transplantation. Lancet, 1989, 2 (8676), 1405-1406.
82. Choi, K. J.; Kim, J. H.; Lee, Y. S.; Kim, J.; Suh, B. S.; Kim, H.; Cho, S.; Sohn, J. H.; Kim, G. E.; Yun, C. O. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene. Ther., 2006, 13 (13), 1010-1020.
83. Fujii, S.; Takayama, T.; Asakura, M.; Aki, K.; Fujimoto, K.; Shimizu, K. Dendritic cell-based cancer immunotherapies. Arch. Immunol. Ther. Exp., (Warsz) 2009, 57 (3), 189-198.
84. Shi, Y.; Liu, C. H.; Roberts, A. I.; Das, J.; Xu, G.; Ren, G.; Zhang, Y.; Zhang, L.; Yuan, Z. R.; Tan, H. S.; Das, G.; Devadas, S. Granulocytemacrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res., 2006, 16 (2), 126-133.
85. Min, L.; Mohammad Isa, S. A.; Shuai, W.; Piang, C. B.; Nih, F. W.; Kotaka, M.; Ruedl, C. Cutting Edge: Granulocyte-macrophage colony-stimulating factor is the major CD8+ T Cell-derived licensing factor for dendritic cell activation. J. Immunol., 2010, 184(9),4625-4629
86. Dranoff, G. GM-CSF-based cancer vaccines. Immunol. Rev., 2002, 188, 147-154.
87. Soiffer, R.; Hodi, F. S.; Haluska, F.; Jung, K.; Gillessen, S.; Singer, S.; Tanabe, K.; Duda, R.; Mentzer, S.; Jaklitsch, M.; Bueno, R.; Clift, S.; Hardy, S.; Neuberg, D.; Mulligan, R.; Webb, I.; Mihm, M.; Dranoff, G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colonystimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol., 2003, 21 (17), 3343-3350.
88. Dranoff, G. GM-CSF-secreting melanoma vaccines. Oncogene, 2003, 22 (20), 3188-3192.
89. Nemunaitis, J.; Nemunaitis, J. Granulocyte-macrophage colonystimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer. Clin. Lung. Cancer, 2003, 5 (3), 148-157.
90. Salgia, R.; Lynch, T.; Skarin, A.; Lucca, J.; Lynch, C.; Jung, K.; Hodi, F. S.; Jaklitsch, M.; Mentzer, S.; Swanson, S.; Lukanich, J.; Bueno, R.; Wain, J.; Mathisen, D.; Wright, C.; Fidias, P.; Donahue, D.; Clift, S.; Hardy, S.; Neuberg, D.; Mulligan, R.; Webb, I.; Sugarbaker, D.; Mihm, M.; Dranoff, G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol., 2003, 21 (4), 624-630.
91. Zarei, S.; Schwenter, F.; Luy, P.; Aurrand-Lions, M.; Morel, P.; Kopf, M.; Dranoff, G.; Mach, N. Role of GM-CSF signaling in cell-based tumor immunization. Blood, 2009, 113 (26), 6658-6668.
92. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y. J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol., 2000, 18, 767-811.
93. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P. S.; McDonnell, T. J.; Mitlianga, P.; Shi, Y. X.; Levin, V. A.; Yung, W. K.; Kyritsis, A. P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 2000, 19, (1), 2-12.
94. Morales, J. K.; Kmieciak, M.; Knutson, K. L.; Bear, H. D.; Manjili, M. H. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat, 2009, 123(1), 39-49
95. Serafini, P.; Carbley, R.; Noonan, K. A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor- producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res., 2004, 64 (17), 6337-6343.
96. Kanerva, A.; Bauerschmitz, G. J.; Yamamoto, M.; Lam, J. T.; Alvarez, R. D.; Siegal, G. P.; Curiel, D. T.; Hemminki, A. A cyclooxygenase- 2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene. Ther., 2004, 11 (6), 552-559.
97. Cho, S. A.; Park, J. H.; Seok, S. H.; Juhn, J. H.; Kim, S. J.; Ji, H. J.; Choo, Y. S. Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. Exp. Toxicol. Pathol., 2006, 57 (4), 321-328.
98. Park, B. H.; Hwang, T.; Liu, T. C.; Sze, D. Y.; Kim, J. S.; Kwon, H. C.; Oh, S. Y.; Han, S. Y.; Yoon, J. H.; Hong, S. H.; Moon, A.; Speth, K.; Park, C.; Ahn, Y. J.; Daneshmand, M.; Rhee, B. G.; Pinedo, H. M.; Bell, J. C.; Kirn, D. H. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol., 2008, 9 (6), 533-542.
99. Pashenkov, M.; Goess, G.; Wagner, C.; Hormann, M.; Jandl, T.; Moser, A.; Britten, C. M.; Smolle, J.; Koller, S.; Mauch, C.; Tantcheva-Poor, I.; Grabbe, S.; Loquai, C.; Esser, S.; Franckson, T.; Schneeberger, A.; Haarmann, C.; Krieg, A. M.; Stingl, G.; Wagner, S. N. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol., 2006, 24 (36), 5716-5724.
100. Raper, S. E.; Chirmule, N.; Lee, F. S.; Wivel, N. A.; Bagg, A.; Gao, G. P.; Wilson, J. M.; Batshaw, M. L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet Metab., 2003, 80 (1-2), 148-158.
101. Brunetti-Pierri, N.; Stapleton, G. E.; Law, M.; Breinholt, J.; Palmer, D. J.; Zuo, Y.; Grove, N. C.; Finegold, M. J.; Rice, K.; Beaudet, A. L.; Mullins, C. E.; Ng, P. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol. Ther., 2009, 17 (2), 327-333.
102. Brunetti-Pierri, N.; Palmer, D. J.; Beaudet, A. L.; Carey, K. D.; Finegold, M.; Ng, P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene. Ther., 2004, 15 (1), 35-46.
103. Brunetti-Pierri, N.; Palmer, D. J.; Mane, V.; Finegold, M.; Beaudet, A. L.; Ng, P. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol. Ther., 2005, 12 (1), 99-106.
104. Nemunaitis, J.; Meyers, T.; Senzer, N.; Cunningham, C.; West, H.; Vallieres, E.; Anthony, S.; Vukelja, S.; Berman, B.; Tully, H.; Pappen, B.; Sarmiento, S.; Arzaga, R.; Duniho, S.; Engardt, S.; Meagher, M.; Cheever, M. A. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol. Ther., 2006, 13 (6), 1185-1191.
105. Choi, H.; Charnsangavej, C.; Faria, S. C.; Macapinlac, H. A.; Burgess, M. A.; Patel, S. R.; Chen, L. L.; Podoloff, D. A.; Benjamin, R. S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol., 2007, 25 (13), 1753-1759.
106. Mita, A. C.; Mita, M. M.; Nawrocki, S. T.; Giles, F. J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res., 2008, 14 (16), 5000-5005.
107. Ouhtit, A.; Matrougui, K.; Bengrine, A.; Koochekpour, S.; Zerfaoui, M.; Yousief, Z. Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front Biosci., 2007, 12, 1260-1270.
108. Tolcher, A. W.; Mita, A.; Lewis, L. D.; Garrett, C. R.; Till, E.; Daud, A. I.; Patnaik, A.; Papadopoulos, K.; Takimoto, C.; Bartels, P.; Keating, A.; Antonia, S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol., 2008, 26 (32), 5198-5203.
109. Senzer, N. Kaufman, H. Amatruda, T. Nemunaitis, M. Reid, T. Daniels, G. Gonzalez, R. Glaspy, J. Whitman, E. Harrington, K. Coffin, R. Nemunaitis, J. A phase II clinical trial of a GM-CSF encoding, second generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. (submitted) 2009, 27(34),5763-5771
110. Hu, J. C.; Coffin, R. S.; Davis, C. J.; Graham, N. J.; Groves, N.; Guest, P. J.; Harrington, K. J.; James, N. D.; Love, C. A.; McNeish, I.; Medley, L. C.; Michael, A.; Nutting, C. M.; Pandha, H. S.; Shorrock, C. A.; Simpson, J.; Steiner, J.; Steven, N. M.; Wright, D.; Coombes, R. C. A phase I study of OncoVEXGM-CSF, a secondgeneration oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 2006, 12 (22), 6737-6747.
111. Liu, B. L.; Robinson, M.; Han, Z. Q.; Branston, R. H.; English, C.; Reay, P.; McGrath, Y.; Thomas, S. K.; Thornton, M.; Bullock, P.; Love, C. A.; Coffin, R. S. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene. Ther., 2003, 10 (4), 292-303.
112. Berard, F.; Blanco, P.; Davoust, J.; Neidhart-Berard, E. M.; Nouri- Shirazi, M.; Taquet, N.; Rimoldi, D.; Cerottini, J. C.; Banchereau, J.; Palucka, A. K. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med., 2000, 192 (11), 1535-1544.
113. Toda, M.; Rabkin, S. D.; Kojima, H.; Martuza, R. L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene. Ther., 1999, 10 (3), 385-393.
114. Kaufman, H. L.; Kim, D. W.; DeRaffele, G.; Mitcham, J.; Coffin, R. S.; Kim-Schulze, S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol., 2010, 17 (3), 718-730.
115. Korn, E. L.; Liu, P. Y.; Lee, S. J.; Chapman, J. A.; Niedzwiecki, D.; Suman, V. J.; Moon, J.; Sondak, V. K.; Atkins, M. B.; Eisenhauer, E. A.; Parulekar, W.; Markovic, S. N.; Saxman, S.; Kirkwood, J. M. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol., 2008, 26 (4), 527-534.
116. Chang, J.; Zhao, X.; Wu, X.; Guo, Y.; Guo, H.; Cao, J.; Lou, D.; Yu, D.; Li, J. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol. Ther., 2009, 8 (8), 676-682.
117. Spitler, L. E.; Weber, R. W.; Allen, R. E.; Meyer, J.; Cruickshank, S.; Garbe, E.; Lin, H. Y.; Soong, S. J. Recombinant human granulocyte- macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J. Immunother., 2009, 32 (6), 632-637.
118. Couch, M.; Saunders, J. K.; O'Malley, B. W. Jr.; Pardoll, D.; Jaffee, E. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope, 2003, 113 (8), 1401-1405.
119. Mathis, J. M.; Stewart, P. L.; Zhu, Z. B.; Curiel, D. T. Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism. Clin. Cancer Res., 2006, 12 (9), 2651-2656.
120. Goldsmith, M. E.; Aguila, A.; Steadman, K.; Martinez, A.; Steinberg, S. M.; Alley, M. C.; Waud, W. R.; Bates, S. E.; Fojo, T. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Mol. Cancer Ther., 2007, 6 (2), 496-505.
121. Akiyama, M.; Thorne, S.; Kirn, D.; Roelvink, P. W.; Einfeld, D. A.; King, C. R.; Wickham, T. J. Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol. Ther., 2004, 9 (2), 218-230.
122. Yu, D. C.; Chen, Y.; Seng, M.; Dilley, J.; Henderson, D. R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res., 1999, 59 (17), 4200-4203.
123. Hsieh, C. L.; Yang, L.; Miao, L.; Yeung, F.; Kao, C.; Yang, H.; Zhau, H. E.; Chung, L. W. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res., 2002, 62 (11), 3084-3092.
124. Bell, J. C.; Lichty, B.; Stojdl, D. Getting oncolytic virus therapies off the ground. Cancer Cell, 2003, 4 (1), 7-11.
125. Takayama, K.; Reynolds, P. N.; Short, J. J.; Kawakami, Y.; Adachi, Y.; Glasgow, J. N.; Rots, M. G.; Krasnykh, V.; Douglas, J. T.; Curiel, D. T. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology, 2003, 309 (2), 282-293.
126. Shayakhmetov, D. M.; Li, Z. Y.; Ni, S.; Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol., 2004, 78 (10), 5368-5381.
127. Glasgow, J. N.; Kremer, E. J.; Hemminki, A.; Siegal, G. P.; Douglas, J. T.; Curiel, D. T. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology, 2004, 324 (1), 103-116.
128. Matthews, K.; Noker, P. E.; Tian, B.; Grimes, S. D.; Fulton, R.; Schweikart, K.; Harris, R.; Aurigemma, R.; Wang, M.; Barnes, M. N.; Siegal, G. P.; Hemminki, A.; Zinn, K.; Curiel, D. T.; Alvarez, R. D. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin. Cancer Res., 2009, 15 (12), 4131-4137.
129. Tong, A. W.; Jay, C. M.; Senzer, N.; Maples, P. B.; Nemunaitis, J. Systemic therapeutic gene delivery for cancer: crafting Paris' arrow. Curr. Gene Ther., 2009, 9 (1), 45-60.
130. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev., 2001, 46, 169-185.
131. Li, W.; Szoka, F. C. Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 2007, 24 (3), 438-449.
132. Hama, S.; Akita, H.; Ito, R.; Mizuguchi, H.; Hayakawa, T.; Harashima, H. Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol. Ther., 2006, 13 (4), 786-794.
133. Price, A.; Limberis, M.; Gruneich, J. A.; Wilson, J. M.; Diamond, S. L. Targeting viral-mediated transduction to the lung airway epithelium with the anti-inflammatory cationic lipid dexamethasonespermine. Mol. Ther., 2005, 12 (3), 502-509.
134. Liu, S.; Ballian, N.; Belaguli, N. S.; Patel, S.; Li, M.; Templeton, N. S.; Gingras, M. C.; Gibbs, R.; Fisher, W.; Brunicardi, F. C. PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas, 2008, 37 (2), 210-220.
135. Thompson, D. H. Adenovirus in a synthetic membrane wrapper: an example of hybrid vigor? ACS Nano, 2008, 2, (5), 821-826.
136. Simoes, S.; Slepushkin, V.; Pires, P.; Gaspar, R.; de Lima, M. P.; Duzgunes, N. Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides. Gene Ther., 1999, 6 (11), 1798-1807.
137. Simoes, S.; Filipe, A.; Faneca, H.; Mano, M.; Penacho, N.; Duzgunes, N.; de Lima, M. P. Cationic liposomes for gene delivery. Exp. Opin. Drug Deliv., 2005, 2 (2), 237-254.
138. Sapra, P.; Tyagi, P.; Allen, T. M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv., 2005, 2 (4), 369-381.
139. Li, S. F.; Wang, X.; Wang, C.; He, L. H.; Shi, Y. H.; Hao, C. F.; Dong, G. L.; Tong, Z. S. [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer.]. Zhonghua Zhong Liu Za Zhi, 2008, 30 (12), 944-646.
140. Shi, Q. Nguyen, A.T. Angell, Y. Deng, D. Na, C. Burgess, K. Roberts, D.D. Brunicardi, F.C. Templeton, N.S. A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass non-specific uptake in vivo. Mol. Ther., 2010, 17(9),1085-1097
141. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010, 464(7291),1067-1070.
142. O'Shea, C. C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.; Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Shen, Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell, 2004, 6 (6), 611-623.
143. Pirollo, K. F.; Chang, E. H. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res., 2008, 68 (5), 1247-1250.
144. Thomas, M. A.; Spencer, J. F.; La Regina, M. C.; Dhar, D.; Tollefson, A. E.; Toth, K.; Wold, W. S. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res., 2006, 66 (3), 1270-1276.
145. Thomas, M. A.; Spencer, J. F.; Toth, K.; Sagartz, J. E.; Phillips, N. J.; Wold, W. S. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol. Ther., 2008, 16 (10), 1665-1673.
146. Lichtenstein, D. L.; Spencer, J. F.; Doronin, K.; Patra, D.; Meyer, J. M.; Shashkova, E. V.; Kuppuswamy, M.; Dhar, D.; Thomas, M. A.; Tollefson, A. E.; Zumstein, L. A.; Wold, W. S.; Toth, K. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther., 2009, 16 (8), 644-654.
147. Jinushi, M.; Hodi, F. S.; Dranoff, G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev., 2008, 222, 287-298.
148. Templeton, N. S.; Lasic, D. D.; Frederik, P. M.; Strey, H. H.; Roberts, D. D.; Pavlakis, G. N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol., 1997, 15 (7), 647-652.